Naropin

Naropin is a brand name of ropivacaine, approved by the FDA in the following formulation(s):

NAROPIN (ropivacaine hydrochloride monohydrate - injectable; injection)

• 
  Manufacturer: APP PHARMS
  
  Approval date: September 24, 1996
  
  Strength(s): 10MG/ML ^[RLD], 2MG/ML, 5MG/ML, 7.5MG/ML
  

Has a generic version of Naropin been approved?

No. There is currently no therapeutically equivalent version of Naropin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Naropin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methods and compositions for the treatment of pain utilizing ropivacaine
  Patent 5,670,524
  Issued: September 23, 1997
  Inventor(s): Eek; Arne Torsten
  Assignee(s): Astra AB
  Use of a pharmaceutically acceptable salt of ropivacaine for the manufacture of a pharmaceutical preparation with sensoric block and minimal motor blockade.
  
  Patent expiration dates:
  
  
  • May 26, 2014
    
    ✓ 
    Patent use: METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Methods and compositions for the treatment of pain utilizing ropivacaine
  Patent 5,834,489
  Issued: November 10, 1998
  Inventor(s): Eek; Arne Torsten
  Assignee(s): AB Astra
  Use of a pharmaceutically acceptable salt of ropivacaine for the manufacture of a pharmaceutical preparation with sensoric block and minimal motor blockade.
  
  Patent expiration dates:
  
  
  • May 26, 2014
    
    ✓ 
    Patent use: METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Naropin Consumer Information (Wolters Kluwer)
• Naropin Consumer Information (Cerner Multum)
• Naropin Advanced Consumer Information (Micromedex)
• Ropivacaine Consumer Information (Wolters Kluwer)
• Ropivacaine Consumer Information (Cerner Multum)
• Ropivacaine Injection Advanced Consumer Information (Micromedex)